Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

The ENVISAGE-TAVI AF trial compared the efficacy and safety of edoxaban with vitamin K antagonists in patients with prevalent or incident atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR). Edoxaban was noninferior to vitamin K antagonists for the composite primary outcome of adverse clinical events (hazard ratio, 1.05; 95% CI, 0.85–1.31). However, edoxaban was associated with a higher risk of major bleeding, primarily due to gastrointestinal bleeding (hazard ratio, 1.40; 95% CI, 1.03–1.91).

The ENVISAGE-TAVI AF trial compared the efficacy and safety of edoxaban with vitamin K antagonists in patients with prevalent or incident atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR). Edoxaban was noninferior to vitamin K antagonists for the composite primary outcome of adverse clinical events (hazard ratio, 1.05; 95% CI, 0.85–1.31). However, edoxaban was associated with a higher risk of major bleeding, primarily due to gastrointestinal bleeding (hazard ratio, 1.40; 95% CI, 1.03–1.91).